Inhibikase Therapeutics, Inc. (IKT)
USD 3.65
(-8.06%)
USD 3.65
(-8.06%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.08 Million | -17.35 Million | -14.29 Million | -1.12 Million | -338.29 Thousand | 714.98 Thousand |
| Net Income | -19.02 Million | -18.05 Million | -14.78 Million | -2.84 Million | -5.72 Million | -2.15 Million |
| Depreciation & Amortization | 177.39 Thousand | 6723.00 | - | - | - | - |
| Deferred income taxes | 464.52 Thousand | - | - | - | - | - |
| Stock-based compensation | 500.14 Thousand | 458.14 Thousand | 1.53 Million | 573.69 Thousand | 1.43 Million | 642.23 Thousand |
| Change in working capital | 234.75 Thousand | 171.18 Thousand | -1.76 Million | -464.63 Thousand | 1.63 Million | 1.51 Million |
| Other non-cash items | -432.98 Thousand | 67 Thousand | 721.62 Thousand | 1.6 Million | 2.31 Million | 709.27 Thousand |
| Investing Cash Flow | 11.65 Million | -16 Million | - | - | - | 87.09 Thousand |
| Investments in PPE | -14.23 Thousand | -243.25 Thousand | - | - | - | - |
| Acquisitions | 14.23 Thousand | 243.25 Thousand | - | - | - | - |
| Investment purchases | -29.42 Million | -20.72 Million | - | - | - | - |
| Sales/Maturities of investments | 41.09 Million | 4.96 Million | - | - | - | - |
| Other Investing Activities | -14.23 Thousand | -243.25 Thousand | - | - | - | 87.09 Thousand |
| Financing Cash Flow | 8.4 Million | -204.76 Thousand | 41.09 Million | 15.06 Million | -22.81 Thousand | -439.19 Thousand |
| Debt repayment | - | -248.91 Thousand | -42.53 Thousand | -272.8 Thousand | -22.81 Thousand | -26.31 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -77.65 Thousand | - | - | - |
| Common Stock Issuance | 8.4 Million | 44.14 Thousand | 41.21 Million | 14.79 Million | - | 1.18 Million |
| Other Financing Activities | -138.55 Thousand | -204.76 Thousand | 41.21 Million | 545.6 Thousand | -22.81 Thousand | -1.59 Million |
| Accounts receivables | 39.88 Thousand | 70.25 Thousand | -110.14 Thousand | - | 472.94 Thousand | -292.16 Thousand |
| Accounts payables | -504.4 Thousand | 61.39 Thousand | -630.9 Thousand | -247.07 Thousand | 47.46 Thousand | 600.71 Thousand |
| Inventory | - | - | 1.3 Million | - | -54.89 Thousand | 950.65 Thousand |
| Other working capital | 699.28 Thousand | 39.52 Thousand | -2.32 Million | -217.56 Thousand | 1.16 Million | 256.72 Thousand |
| Cash at beginning of period | 7.18 Million | 40.75 Million | 13.95 Million | 18.45 Thousand | 379.55 Thousand | 16.66 Thousand |
| Cash at end of period | 9.16 Million | 7.18 Million | 40.75 Million | 13.95 Million | 18.45 Thousand | 379.55 Thousand |
| Capital Expenditure | -14.23 Thousand | -243.25 Thousand | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 1.97 Million | -33.56 Million | 26.79 Million | 13.93 Million | -361.1 Thousand | 362.89 Thousand |
| Free Cash Flow | -18.09 Million | -17.59 Million | -14.29 Million | -1.12 Million | -338.29 Thousand | 714.98 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -4.95 Million | -4.64 Million | -4.17 Million | -19.02 Million | -4.59 Million | -5.77 Million |
| Depreciation & Amortization | 6569.00 | 6568.00 | 6568.00 | 177.39 Thousand | 6583.00 | 159.2 Thousand |
| Deferred income taxes | - | - | -223.17 Thousand | 464.52 Thousand | - | -663.26 Thousand |
| Stock-based compensation | 30.69 Thousand | 53.43 Thousand | 122.24 Thousand | 500.14 Thousand | 129.78 Thousand | 124.84 Thousand |
| Change in working capital | -132.03 Thousand | 722.61 Thousand | 592.43 Thousand | 234.75 Thousand | 336.46 Thousand | 928.52 Thousand |
| Other non-cash items | -352.59 Thousand | -412.69 Thousand | 237.43 Thousand | -432.98 Thousand | 17.28 Thousand | 663.26 Thousand |
| Investing Cash Flow | 2.54 Million | -3.31 Million | -2.11 Million | 11.65 Million | 17.06 Million | 2.54 Million |
| Investments in PPE | 4.00 | - | 14.23 Thousand | -14.23 Thousand | - | -14.23 Thousand |
| Acquisitions | - | - | -14.23 Thousand | 14.23 Thousand | - | 14.23 Thousand |
| Investment purchases | -776.97 Thousand | -8.43 Million | -8.79 Million | -29.42 Million | -1.94 Million | 2.92 Million |
| Sales/Maturities of investments | 3.32 Million | 5.12 Million | 6.68 Million | 41.09 Million | 19 Million | -365.65 Thousand |
| Other Investing Activities | 2.54 Million | -3.31 Million | -2.11 Million | -14.23 Thousand | 17.06 Million | -14.23 Thousand |
| Financing Cash Flow | 3.24 Million | 366.99 Thousand | -138.1 Thousand | 8.4 Million | 70.00 | -35.98 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | 35.98 Thousand | - | - | -35.98 Thousand |
| Common Stock Issuance | 3.24 Million | 366.99 Thousand | -138.1 Thousand | 8.4 Million | 70.00 | -35.98 Thousand |
| Other Financing Activities | 30.6 Thousand | -30.6 Thousand | -138.1 Thousand | -138.55 Thousand | 70.00 | - |
| Accounts receivables | - | - | - | 39.88 Thousand | 79.6 Thousand | -15.08 Thousand |
| Accounts payables | 396.43 Thousand | 479.26 Thousand | -87.79 Thousand | -504.4 Thousand | -19.58 Thousand | -204.93 Thousand |
| Inventory | - | - | -249.44 Thousand | - | 249.44 Thousand | - |
| Other working capital | -528.46 Thousand | 243.34 Thousand | 680.23 Thousand | 699.28 Thousand | 27 Thousand | 1.14 Million |
| Cash at beginning of period | 2.35 Million | 9.16 Million | 14.86 Million | 7.18 Million | 1.9 Million | 3.95 Million |
| Cash at end of period | 3.08 Million | 2.35 Million | 9.16 Million | 9.16 Million | 14.86 Million | 1.9 Million |
| Capital Expenditure | 4.00 | - | 14.23 Thousand | -14.23 Thousand | - | -14.23 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 733.1 Thousand | -6.81 Million | -5.69 Million | 1.97 Million | 12.95 Million | -2.05 Million |
| Free Cash Flow | -5.05 Million | -3.86 Million | -3.42 Million | -18.09 Million | -4.1 Million | -4.57 Million |
CDNTF
MANVF
002681
1897
DFS
300278